Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Trough Level- and Clinical-based Spacing of Infliximab Infusions in Patients With IBD in Deep Remission

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age greater than 18 years~  * Patients with a diagnosis of Crohn's disease or ulcerative colitis according to clinical, biological, morphological and endoscopic criteria defined by the ECCO guidelines22, 23~ * Patients in deep remission since at least 6 months17:~    * CDAI \< 150 for CD, Partial Mayo score \< 3 for UC~   * CRP (C reactive protein) \< 10 mg/l~   * CDEIS \< 6 (\<3 in each segment) for CD, Mayo endoscopic subscore of 0 or 1 for UC~   * For CD patients with small bowel disease: No ulceration on MRI, only asymptomatic fibrotic stenosis without inflammation and retro dilatation. No ulceration on wireless capsule endoscopy if feasible~   * For patients with perianal disease: No active draining fistula, or perianal abscess on clinical exam and MRI~ * Treatment with infliximab at stable dose (5mg/kg) with a stable interval for at least 4 months~ * Infliximab trough level \> 3 ug/ml~ * No change in other IBD therapies in the past 4 months~ * Signed informed consent form~ * Subjects must be able to attend all scheduled visits and to comply with all trial procedures~ * Subjects must be covered by public health insurance~Exclusion Criteria:~* Subject unable to read or/and write~  * Planned longer stay outside the region that prevents compliance with the visit plan~ * Subject who are in a dependency or employment with the sponsor or the investigator~ * Participation in another clinical trial or administration of an unapproved drug within the last 4 weeks before the screening date~ * Previous withdrawal or spacing over 8 weeks of infliximab therapy~ * Infliximab therapy at 10 mg/kg~ * Patients who have presented a severe acute or delayed reaction to infliximab.~ * Active perianal/abdominal fistulae at time of inclusion, defined by active drainage~ * Patients with ostomy or ileoanal pouch~ * Pregnancy or planned pregnancy during the study~ * Inability to follow study procedures as judged by the investigator~ * Steroid use ≤3 months prior to screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- clinically-based spacing (Type: OTHER): All patients (as there are free from symptoms) after inclusion will have a spacing of their infliximab infusion interval which will be maintained until the end of the study.
- Trough level-based spacing (Type: OTHER): Only patients with a baseline infliximab trough level ≥ 7 ug/ml will have a spacing of their infliximab infusion interval which will be maintained until the end of the study. Patients with a baseline infliximab trough level \< 7 ug/ml will keep their baseline infliximab infusion interval until the end of the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues